£80.0M
The financing round was led by Sofinnova Partners and will fund upcoming clinical trials for kidney disease treatments.
PT
Purespring Therapeutics
Purespring Therapeutics develops adeno-associated viral gene therapies for renal diseases.
London, UK—Founded 2020
£80.0MTotal raised
Purespring Therapeutics develops novel gene therapies designed to treat various forms of kidney disease by targeting specialised renal cells.
Team
Julian Hanak
CEO
Julian brings biotech operating experience from leadership roles at Purespring Therapeutics, Biogen, and Nightstar Therapeutics. He currently serves as entrepreneur in residence at the University of Bristol.
LinkedIn